Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
NTLA
NTLA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NTLA News
Intellia Therapeutics Regulatory Progress and Market Potential
Feb 08 2026
NASDAQ.COM
Analysis of Intellia Therapeutics' Stock Recovery
Feb 07 2026
Fool
FDA Lifts Clinical Hold on Intellia's IND for ATTRv-PN Trial
Jan 27 2026
Benzinga
FDA Lifts Clinical Hold on Intellia's Phase 3 Trial
Jan 27 2026
Newsfilter
FDA Lifts Clinical Hold on Nex-Z Trial for ATTRv-PN
Jan 27 2026
stocktwits
HCA Healthcare Surges After Strong Q4 Earnings and Upgraded FY25 Guidance
Jan 27 2026
Benzinga
Intellia's Gene Therapy Trial Resumes After FDA Hold Lifted
Jan 27 2026
seekingalpha
ARK Invest Deepens AI Chip and Gene Editing Investments, Sells 86K Tesla Shares
Jan 19 2026
seekingalpha
U.S. Stock Futures Rise as Market Sentiment Turns Neutral
Jan 16 2026
stocktwits
ARK Invest Acquires 56,769 Shares of Intellia, Stock Rises 2%
Jan 16 2026
stocktwits
NTLA Stock Fluctuation: 52-Week Low of $5.90 and High of $28.25
Jan 12 2026
NASDAQ.COM
ARK Invest Focuses on Innovation Themes, Increases Stake in Komatsu and Others
Jan 12 2026
seekingalpha
Intellia Therapeutics CEO John M. Leonard Sells 34,146 Shares for $314,484
Jan 12 2026
Fool
Intellia Therapeutics CEO John M. Leonard Sells 34,146 Shares for $314,484
Jan 12 2026
NASDAQ.COM
Intellia Therapeutics Reports $413M Cash Burn, Facing Funding Pressure
Jan 03 2026
Yahoo Finance
Intellia Grants 22,800 RSUs to Attract New Employees Under 2024 Inducement Plan
Jan 02 2026
Globenewswire
Show More News
